International Health Tech R&D Pilot Programme shortlist revealed
Shortlisted companies moving to stage 2 of our International Health Tech R&D Pilot Programme announced
7th March 2023
The NHSA is delighted to announce the 15 shortlisted companies that are moving to stage 2 of our International Health Tech R&D Pilot Programme.
The successful companies are (in alphabetical order):
- Cognishine Therapy and Education
- Cordio Medical
- Donisi health
- GistMD
- Ikko Health
- ImPlio
- Kemtai
- Nanovation
- Neurotrigger
- Pathkeeper
- Pulsenmore
- QLOG Technologies
- Sherman Diagnostics
- Visionsense
- Votis
The shortlisted companies will now work with NHSA members to develop their project plans to bring world leading R&D to the UK. They will receive support from the NHSA, the UK Israel Tech Hub and HealthIL to develop their ideas and deliver maximum impact for their business and UK patients.
The International Health Tech R&D pilot programme is led by the NHSA in the UK and the Israeli Innovation Authority in Israel to identify unmet clinical needs in the UK and identify potential solutions. We connect cutting edge health technologies to UK research and innovation expertise to stimulate transnational partnerships, accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to global markets, and advance the development of discoveries for the benefit of patients all over the world.
Related News Articles
Poor diets in the North go hand-in-hand with the highest rates of cancer, diabetes, heart disease and food insecurity in the country
Northern regions have some of the poorest diets in England, putting them at risk of conditions such as obesity, hypertension and other preventable diseases.
Read the articleStatement from Chief Executive Hannah Davies following The Health Foundation report on premature mortality rates
A statement on behalf of the Northern Health Science Alliance
Read the articleChief Executive of the Northern Health Science Alliance comments on 10 Year Health Plan announcement
Statement from Chief Executive Hannah Davies
Read the article